A central or central venous line is another name for a central venous catheter. It is a flexible tube put into the superior vena cava, a big vein that runs below the collarbone’s right side to the heart. A central venous catheter is used to administer a variety of fluids that are simple to inject into patients’ bodies. Intravenous fluids, blood transfusions, and chemotherapy medications are among the fluids.
The market for the central venous catheter in 2021 was USD 1.18 billion and will reach USD 1.93 billion by 2030, growing at a 5.48% CAGR.
The number of chronic diseases like cancer, end-stage renal disease, and others is expected to rise, as well as the geriatric population and the use of tip location devices. These factors will boost the worldwide central venous catheter market. The total central venous catheter market will be driven by additional factors such as advantageous insurance and reimbursement policies, technical advancements, and early adoption of diagnostic methods.
The market for central venous catheters is rising due to factors such as the rising number of patients with cancer and chronic illnesses, the widespread use of antimicrobial catheters, new technological developments, and the introduction of numerous new products.
The rising prevalence of cancer and chronic diseases, particularly in geriatric patients, technological improvements, and the widespread acceptance of antimicrobial catheters are the main factors driving the market’s expansion.
With around 1,918,030 new cases reported in 2022, the National Center for Health reports that cancer was the second greatest cause of mortality worldwide. Worldwide, cancer was the cause of 609,360 fatalities. Furthermore, according to the WHO, the number of new cases is predicted to increase by almost 70% by 2030. Central venous catheters make it easier to administer chemotherapy medications, and cancer patients worldwide are increasingly using antimicrobial catheters.
Market growth is being hampered by factors including deep vein thrombosis (DVT), infections, thrombophlebitis, and dislodgement brought on by the usage of catheters.
Due to its unique advantages, including its capacity to carry fluids into a larger vein and stay in the body for longer than normal, the demand for central venous catheters is constantly rising around the world. Future prospects should be plentiful due to the increase in demand for these catheters and the increase in global government funding for surgical equipment R&D.
- By Product Type, the market was considerably controlled by the Non-Tunnelled Catheters segment in 2020. The overall expansion of this market is being driven by an increase in incisions worldwide and a rise in awareness of the use of non-tunneled catheters during emergencies.
- On the basis of Property, the “Antimicrobial Catheters” market sector held a 35.732% market share in 2020. Global attention is increasingly being paid to preventing HAIs (Healthcare-Associated Infections), fostering the expansion of this market.
- With 17.832% of the market share in 2020, the “Double Lumen” sector completely ruled the market based on design. In 2020, the combined market shares for the Double-Lumen segment in the United States, Australia, Canada, China, and Japan could reach USD 161.134 Mn. The number of ARF (Acute Renal Failure) treatments being provided in ICUs is driving this region’s market expansion.
- Based on composition, the “Silicone” segment ruled the market in 2020 with a 14.372% share. In general, silicone material catheters are favored because they are flexible and can be used for a long time as tunneled CVC (Central Venous Catheters).
- Due to the increasing utilization of CVCs in ICUs and CICUs (cardiac critical care units) across the globe, the “Hospitals” sector largely led the market on the basis of End-User with a constant CAGR.
North America was the market leader in 2020, with a steady CAGR. In 2020, the United States held about 33.917% (or USD 384.763 Mn) of the global market share. The fastest growth rate was in Asia-Pacific, with China contributing up to a CAGR of 7.368%. With an overall CAGR of 5.137% in Europe, Germany had the largest market share, and by 2030 the rest of Europe’s market will be worth USD 223.135 Mn.
- Boston Scientific Corporation
- AngioDynamics, Inc.
- B. Braun Melsungen AG
- Becton, Dickinson & Company
- Biosensors International Group Ltd.
- Cook Medical, Inc.
- Smiths Medical
- BARD Care
- Guangdong Baihe Medical Technology Co. Ltd.
- Intra Special Catheters GmbH
- ConMed Corporation
- Edwards Lifesciences Corporation
- ISO-MED, INC.
- Medical Components, Inc.
- PRODIMED ZI
- SCW Medicath Ltd.
- Henan Tuoren Medical Device Co. Ltd.
- Kimal PLC
- Troge Medical GmbH
- Lepu Medical Technology (Beijing) Co. Ltd
- ZOLL Medical Corporation
- Terumo Corporation
- Teleflex Inc.
- Vygon SA
- Vogt Medical Vertrieb GmbH
The market for the central venous catheter in 2021 was USD 1.18 billion and will reach USD 1.93 billion by 2030, growing at a 5.48% CAGR. The global increase in surgeries and the incidence of chronic diseases are responsible for the overall growth of this market.